Davidson & Garrard’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
$10.1M Sell
113,099
-966
-0.8% -$73.5K 2.37% 3
2017
Q2
$8.27M Sell
114,065
-912
-0.8% -$61.3K 1.97% 8
2017
Q1
$7.49M Buy
114,977
+673
+0.6% +$42.3K 1.78% 12
2016
Q4
$7.16M Buy
114,304
+1,360
+1% +$83K 1.78% 11
2016
Q3
$7.12M Buy
112,944
+630
+0.6% +$40.8K 1.77% 12
2016
Q2
$6.95M Sell
112,314
-138
-0.1% -$8.41K 1.71% 11
2016
Q1
$6.42M Buy
112,452
+4,258
+4% +$237K 1.64% 12
2015
Q4
$6.41M Buy
108,194
+1,743
+2% +$100K 1.59% 13
2015
Q3
$5.79M Sell
106,451
-373
-0.3% -$24.3K 1.5% 13
2015
Q2
$7.18M Buy
106,824
+4,955
+5% +$323K 1.66% 9
2015
Q1
$5.96M Buy
101,869
+15,277
+18% +$923K 1.36% 16
2014
Q4
$5.67M Buy
86,592
+3,085
+4% +$194K 1.31% 20
2014
Q3
$4.82M Buy
83,507
+63,949
+327% +$3.55M 1.17% 28
2014
Q2
$1.1M Buy
19,558
+480
+3% +$25.2K 0.27% 100
2014
Q1
$981K Sell
19,078
-295
-2% -$14.9K 0.24% 103
2013
Q4
$1.02M Buy
19,373
+462
+2% +$22.7K 0.26% 97
2013
Q3
$846K Buy
18,911
+50
+0.3% +$2.22K 0.24% 99
2013
Q2
$780K Buy
+18,861
New +$825K 0.23% 98

Other funds holding ABBV

Davidson & Garrard's ABBV Position: Q3 2017 in Review

Davidson & Garrard reduced its AbbVie (ABBV) stake by 0.85% in Q3 2017, selling an estimated $73.5K and leaving 113,099 shares worth $10.1M. The position accounts for 2.37% of the portfolio, ranked #3.

Davidson & Garrard first reported a position in ABBV in Q2 2013 and has held it in 18 quarters since. 1,797 funds tracked by Wall St. Rank hold ABBV as of Q3 2017.

  • Davidson & Garrard held 113,099 shares of AbbVie worth $10.1M as of Q3 2017.
  • Davidson & Garrard sold 966 AbbVie shares in Q3 2017, an estimated $73.5K.
  • AbbVie made up 2.37% of Davidson & Garrard's portfolio in Q3 2017, its #3 holding.
  • Davidson & Garrard first reported a position in AbbVie in Q2 2013 and has held it in 18 quarters since.
  • 1,797 funds tracked by Wall St. Rank held AbbVie as of Q3 2017.

Based on Davidson & Garrard's 13F filing for Q3 2017, filed 7 Nov 2017.